Proactive Investors - Run By Investors For Investors

Namaste Technologies Inc comes out of quiet period and looks to Cuba for opportunities

Namaste Technologies came out of its quiet period and was broadcasting from Cuba last week, as the company said it was looking for further opportunities
Namaste Technologies Inc comes out of quiet period and looks to Cuba for opportunities
Namaste announced it was exploring opportunities in Cuba

It's been a challenging few months for Namaste Technologies Inc (CVE:N) (OTCQB: NXTTF).

The cannabis company has recently been in a quiet period, but announced last week it had raised C$51.7 million in a mammoth financing deal. 

The company said funds raised are expected to be used for inventory and supplies, capital improvements, expansion of e-commerce platforms and customer base.

READ: Namaste Technologies unveils massive $51 million financing deal; shares soar

The company also announced it was exploring opportunities in Cuba.

Namaste Technologies has an extremely dedicated following on YouTube, with thousands of fans tuning in for its weekly "Namaste 420 Live" video. 

"I work countless hours, I'm travelling the world -- I haven't even heard anyone speaking about the opportunities in Cuba, meanwhile, Namaste is here, on the ground - exploring, researching, and looking for unique opportunities," said Dollinger in a YouTube video last week.

Dollinger pointed out the fact that one of the industries Cuba is best known for is aligned with what Namaste does. 

"That's what makes Namaste different, we think outside the box," said Dollinger in his webcast from Cuba. "We're here, doing shows like this."

Shares of Namaste were at C$1.76 on Monday.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use